OOIR: Observatory of International Research

Papers

(The H4-Index of Journal of Nuclear Medicine is 47. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
Practicing Medicine in Wartime Ukraine	117
One Bite from the Apple, One Bite from the Orange in the PRECISE-MDT Study	110
Serial [ ¹⁸ F]AlF-NOTA-FAPI PET/CT and CT Angiography in Type B Aortic Dissection Before and After Thoracic Endovascular Aortic Repair	107
Synergy Between Radiopharmaceutical Therapy and Immune Response: Deciphering the Underpinning Mechanisms for Future Actions	102
Determining Hemodynamically Significant Coronary Artery Disease: Patient-Specific Cutoffs in Quantitative Myocardial Blood Flow Using [¹⁵O]H₂O PET Imaging	86
Redesigned Curricula, Stringent Licensing Criteria, and Integrated Independence Are Conditions for a Bright Future for Nuclear Medicine in the United States	83
MIRD Pamphlet No. 28, Part 2: Comparative Evaluation of MIRDcalc Dosimetry Software Across a Compendium of Diagnostic Radiopharmaceuticals	82
Quantitative Spatial Profiling of Antibody Delivery and Target Engagement Using Optically Labeled Antibodies	79
Radiolabeled Somatostatin Receptor Antagonist Versus Agonist for Peptide Receptor Radionuclide Therapy in Patients with Therapy-Resistant Meningioma: PROMENADE Phase 0 Study	76
Ambient Light Resistant Shortwave Infrared Fluorescence Imaging for Preclinical Tumor Delineation via the pH Low-Insertion Peptide Conjugated to Indocyanine Green	72
Response to the FDA Dosage Optimization Draft Guidance for Radiopharmaceutical Therapies	72
Diagnostic Performance of [ ¹⁸ F]PSMA-1007 PET/CT on Proven PSMA-Positive Hepatocellular Carcinoma: A Prospective Clinical Study	72
⁶⁸Ga-PSMA PET/CT–Based Atlas for Prostate Bed Recurrence After Radical Prostatectomy: Clinical Implications for Salvage Radiation Therapy Contouring Guidelines	71
Biochemical Recurrence–Free Survival After Radical Prostatectomy in Patients with High-Risk Prostate Cancer: A Nationwide Study of PSMA PET/CT Versus Conventional Imaging	71
Impact of Single-Time-Point Estimates of¹⁷⁷Lu-PRRT Absorbed Doses on Patient Management: Validation of a Trained Multiple-Linear-Regression Model in 159 Patients and 477 Therapy Cycles	70
State of the Art: Precision Surgery Guided by Intraoperative Molecular Imaging	70
Receptor-Targeted Peptide Conjugates Based on Diphosphines Enable Preparation of^99mTc and¹⁸⁸Re Theranostic Agents for Prostate Cancer	70
Quantitative Deauville Scoring to Uncover Prognostic Information from ¹⁸F-FDG PET–Based Response Assessment: Data from the EuroNet-PHL-C1 Trial	69
Composite Prediction Score to Interpret Bone Focal Uptake in Hormone-Sensitive Prostate Cancer Patients Imaged with [¹⁸F]PSMA-1007 PET/CT	67
Localized In Vivo Prodrug Activation Using Radionuclides	66
Interspecies Variability in Biodistribution and PET Imaging Performance of [¹⁸F]Di-PyL: A Dimeric, PSMA-Targeted PET Agent for Prostate Cancer	65
Nuclear Medicine AI in Action: The Bethesda Report (AI Summit 2024)	64
Preclinical Evaluation of²²⁶Ac as a Theranostic Agent: Imaging, Dosimetry, and Therapy	64
¹⁷⁷Lu-DOTATATE in Combination with PARP Inhibitor Olaparib Is Feasible in Patients with Somatostatin-Positive Tumors: Results from the LuPARP Phase I Trial	63
Clinical Experience with [²²⁵Ac]Ac-PSMA Treatment in Patients with [¹⁷⁷Lu]Lu-PSMA–Refractory Metastatic Castration-Resistant Prostate Cancer	63

Beyond Average: α-Particle Distribution and Dose Heterogeneity in Bone Metastatic Prostate Cancer	63
Renal Medullary Carcinoma: Utility of [ ¹⁸ F]FDG PET/CT in Evaluating Extent of Disease and Impact on Treatment Management	62
PCa Detection in PI-RADS 4 and 5 Lesions: Comparison of [ ⁶⁸ Ga]Ga-PSMA-11 PET/CT–Guided Robot-Assisted Biopsy Versus mpMRI Cognitive-Fusion TRUS-Gui	61
Prostate-Specific Membrane Antigen–Targeted Imaging and Its Correlation with HOXB13 Expression	60
Positron Range Correction Helps Enhance the Image Quality of Cardiac⁸²Rb PET/CT	60
Theranostics Explained: A Personalized Approach to Cancer Care	58
CCK₂Receptor Ligand [⁶⁸Ga]Ga-DOTA-CCK-66 PET/CT Outperforms [⁶⁸Ga]Ga-DOTATOC PET/CT in a Patient with Small Cell Lung Cancer	58
Delta-like Ligand 3Directed ²²⁵ Ac Radioimmunotherapy in Neuroendocrine Lung and Prostate Cancer Models	58
Prognostic Value of Comprehensive Analysis of Metastatic Prostate Tumor Changes from First to Last [ ¹⁷⁷ Lu]Lu-PSMA Therapy Injections Through Serial	57
Diagnostic Radiopharmaceuticals: A Sustainable Path to the Improvement of Patient Care	57
[ ¹⁷⁷ Lu]Lu-DOTATATE for Recurrent Meningioma (LUMEN-1, EORTC-2334-BTG): Study Protocol for a Randomized Phase II Trial	57
The Role of Molecular Imaging in Precision Oncology	57
Artificial Intelligence–Powered Quantification of Flortaucipir PET for Detecting Tau Pathology	56
α-Synuclein Seeding Amplification Assay: A Breakthrough in Diagnosing Parkinson Disease?	55
¹⁷⁷Lu-PSMA Radiopharmaceutical Therapy or Cabazitaxel?	52
Reply to “Foregoing Nonclinical Dosimetry Studies to Support First-in-Human Studies of Certain PET Radiopharmaceuticals”	52
Intrapatient 16α-[¹⁸F]Fluoro-17β-Estradiol PET Heterogeneity as a Prognostic Factor for Endocrine Therapy Response and Survival in Patients with Estrogen Receptor–Positive Metastatic Breast	51
Challenges with¹⁷⁷Lu-PSMA-617 Radiopharmaceutical Therapy in Clinical Practice	51
Widespread Prostate Cancer Osseous Metastases: Negative on ¹⁸ F-Piflufolastat PET but Positive on ¹⁸	50
2022 SNMMI Highlights Lecture: Oncology and Therapy, Part 2	49
First-in-Human Study of [¹¹C]NCGG401 for Imaging Colony-Stimulating Factor 1 Receptors in the Brain	49
The Research Post	49
Funding Reductions Threaten the Future of Medical Innovation	47
Preclinical Evaluation of ⁶⁴ Cu-LNTH-1363S to Detect Cardiac FAP-Positive Fibroblasts Using PET Imaging	47
Development and Preclinical Evaluation of [⁶⁴Cu]Cu-NOTA-ABDB6: A CD70 and Albumin Dual-Binding Tracer with Improved Pharmacokinetics	47
Biodistribution, Safety Profile, and Radiation Dosimetry of [¹⁸F]SYN2, a PET Cardiac Perfusion Tracer, in Healthy Subjects	47